Up to 7 years treatment with GLP-1 receptor agonist in patients with type 2 diabetes didn't seem to increase pancreatic cancer risk in a large population-based cohort study.
While tirzepatide has bagged FDA approval for treating T2D and for weight loss, the critical question remains can it also safeguard the kidneys, a key objective in diabetes care?
Multinational joint consensus statement summarized current evidence on diabetes stigma and discrimination and made recommendations for stakeholders including healthcare providers.